HJ Science

HJ Science (Ticker: 6132 HK) develops experimental medicines for immune system disorders, metabolic conditions and cancer. Founded in 2017, HJ Science is a clinical-stage company whose main drug candidates are still being tested and have not reached broad commercial launch. Its three main candidates target atopic dermatitis and psoriasis, type 2 diabetes and potential weight-management uses, and a form of lung cancer linked to a specific genetic mutation. The company intends to use IPO proceeds for research and development, product capacity, brand promotion, business development, working capital and strategic acquisitions.

The scheduled listing date on Hong Kong Stock Exchange was June 23, 2026. The offering comprises 13,600,000 shares at a confirmed price of HKD 81.80 per share. At the confirmed offer price, the base offering represents HKD 1.11 billion, approximately $141.76 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $768.00 million.